Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: BT does not have a significant influence on response rates, progression-free survival, and overall survival Radiation = nonradiation-based BT https://t.co/s2KkDvtc2S
@MichaelDJain et al: outcomes of bridging pts to CAR-T • 275 pts axi-cel, 52% bridged •’worse baseline risk so outcome ⬇️ but • when propensity score matched, outcomes ➡️ • RT bridging equiv to non-RT Reassuring that bridging does not ⬇️ outcomes. https…
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium https://t.co/HJLVtgykrI